Skip to Content

Hematology

Breaking down barriers to blood disease studies

Hematology

Clinical research continues to be a vital element in understanding and treating benign and malignant rare hematology diseases including:

  • Hemolytic Anemia
    • Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • Cold Agglutinin Disease (CAD)
    • Autoimmune Hemolytic Anemia (AIHA)
  • Hematological Malignancies (Leukemia, Lymphoma, etc.)

Before you begin your next hematology study, be sure to ask yourself the following questions:

  • Do you have strong relationships with your clinical sites?
  • Can you find the right type and number of patients for your trial?
  • Do you have expertise in operations and logistics for global trials?
  • Are you working with an experienced global CRO?

 

Flexibility equals success

Biorasi can help your company identify and overcome common obstacles to meeting hematology clinical trial milestones by:

  • Understanding clinical trial recruitment and retention challenges for hemolytic anemia and other rare hematology diseases, matching your prospective patients by etiology and geography.
  • Priding ourselves on our international reach and expertise, customizing our recruitment efforts to include patient-centric strategies — using patient registries, advocacy groups, key opinion leaders (KOLs), and other solutions that optimize global enrollment.
  • Realizing the importance of decentralized solutions to expand access to patients far from study sites, leveraging technology and patient-focused strategies to improve identification, engagement, and retention.